SMAD2 and cardiac hypertrophy: A comprehensive analysis of the key signaling pathways involved in atherosclerosis-associated cardiac hypertrophy was considered necessary to facilitate a complete understanding of this pathology and to evaluate the therapeutic potential of EVs, both transfected and non-transfected with Smad2/3 siRNA.